NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-040-2012-0-IL-58 Chimeric Antigen Receptors Targeting B-cell Maturation Antigen IL DIV 278003 Issued
NCI E-097-2018-0-KR-11 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES KR National Stage 10-2020-7029302 Pending
NCI E-105-2012-0-IE-01 PHARMACEUTICAL COMPOSITION COMPRISING HOST CELLS ENCODING ANTI-NY-ESO-1 T CELL RECEPTORS IE EP 20201340.5 Issued
NCI E-105-2012-0-DE-01 PHARMACEUTICAL COMPOSITION COMPRISING HOST CELLS ENCODING ANTI-NY-ESO-1 T CELL RECEPTORS DE EP 20201340.5 Issued
NCI E-105-2012-0-IT-01 PHARMACEUTICAL COMPOSITION COMPRISING HOST CELLS ENCODING ANTI-NY-ESO-1 T CELL RECEPTORS IT EP 20201340.5 Issued
NCI E-105-2012-0-ES-01 PHARMACEUTICAL COMPOSITION COMPRISING HOST CELLS ENCODING ANTI-NY-ESO-1 T CELL RECEPTORS ES EP 20201340.5 Issued
NCI E-105-2012-0-FR-01 PHARMACEUTICAL COMPOSITION COMPRISING HOST CELLS ENCODING ANTI-NY-ESO-1 T CELL RECEPTORS FR EP 20201340.5 Issued
NCI E-105-2012-0-EP-27 Murine Anti-NY-ESO-1 T Cell Receptors EP DIV 20201340.5 Issued
NCI E-105-2012-0-GB-01 PHARMACEUTICAL COMPOSITION COMPRISING HOST CELLS ENCODING ANTI-NY-ESO-1 T CELL RECEPTORS GB EP 20201340.5 Issued
NCI E-174-2019-0-CN-03 A VIRAL EXPOSURE SIGNATURE FOR DETECTION OF EARLY STAGE HEPATOCELLULAR CARCINOMA CN National Stage 202080071446.7 Issued
NCI E-174-2019-0-PCT-02 A VIRAL EXPOSURE SIGNATURE FOR DETECTION OF EARLY STAGE HEPATOCELLULAR CARCINOMA PCT PCT PCT/US2020/055077 Expired
NHLBI E-219-2018-2-US-03 METHOD AND SYSTEM FOR AUTOMATICALLY GENERATING AND ANALYZING FULLY QUANTITATIVE PIXEL-WISE MYOCARDIAL BLOOD FLOW AND MYOCARDIAL PERFUSION RESERVE MAPS TO DETECT ISCHEMIC HEART DISEASE USING CARDIAC PERFUSION MAGNETIC RESONANCE IMAGING US National Stage 17/046,193 Abandoned
NCI E-100-2018-0-EP-03 3-O-SULFO-GALACTOSYLCERAMIDE ANALOGS AS ACTIVATORS OF
TYPE II NKT CELLS AND USES THEREOF 		EP National Stage 19716658.0 Pending
NIAID E-185-2015-0-US-06 EXPRESSION VECTOR DELIVERY SYSTEM AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE US DIV 17/064,496 12383618 Issued PDF
NCI E-230-2012-0-KR-62 T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3 KR DIV 10-2020-7028713 Issued
NIAID E-198-2025-0-US-10 VIRAL SEROLOGY ASSAYS US 63/087,956 Expired
NEI E-050-2015-0-JP-14 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa JP DIV 2020-167984 Abandoned
NCI E-189-2020-0-US-01 HLA CLASS II-RESTRICTED DQ T CELL RECEPTORS AGAINST RAS WITH G13D MUTATION US 63/086,674 Abandoned
NCI E-077-2017-0-US-04 CATIONIC LIPID VACCINE COMPOSITIONS AND METHODS OF USE US CON 17/061,464 12201685 Issued PDF
NIAID E-031-2026-0-US-02 Antigenic Epstein Barr Virus Polypeptides US CON 17/061,146 11617780 Issued PDF
NIAID E-031-2026-0-JP-01 Antigenic Epstein Barr Virus Polypeptides JP National Stage 2020-554517 Issued
NHLBI E-078-2019-0-US-03 HELICAL GUIDEWIRES AND RELATED SYSTEMS US ORD 17/038,095 Abandoned
NIAID E-131-2020-5-US-01 Anti-Coronavirus Antibodies And Methods Of Use US 63/085,042 Abandoned
NCI E-105-2018-0-CA-04 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data CA National Stage 3095485 Issued
NHLBI E-241-2010-0-KR-17 Capsid-deficient AAV vectors, compositions, and methods for vector preparation and gene delivery KR DIV 10-2020-7027994 Issued
NCI E-105-2018-0-US-06 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data US National Stage 17/042,765 Abandoned
NCI E-085-2013-0-HK-27 CD8+ T CELLS THAT ALSO EXPRESS PD-1 AND/OR TIM-3 FOR THE
TREATMENT OF CANCER 		HK EP 42020016957.1 Pending
NCI E-100-2018-0-US-04 3-O-SULFO-GALACTOSYLCERAMIDE ANALOGS AS ACTIVATORS OF TYPE II NKT CELLS AND USES THEREOF US National Stage 17/041,604 12268700 Issued PDF
NHLBI E-076-2021-0-US-03 Systems And Methods For Applying Pressure To A Bodily Organ US ORD 17/032,283 12213881 Issued PDF
NHGRI E-185-2014-0-US-12 VIRAL GENE THERAPY AS TREATMENT FOR CHOLESTEROL STORAGE DISEASE OR DISORDER US DIV 17/033,166 12201658 Issued PDF
NCI E-230-2012-0-HK-61 T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3 HK EP 42020016865.6 Issued
NHLBI E-076-2021-0-PCT-02 Systems And Methods For Applying Pressure To A Bodily Organ PCT PCT PCT/US2020/052690 Expired
NIAAA E-049-2016-0-US-01 COMPOUND FOR USE IN PROTECTING SKIN US CON 17/032,616 Pending
NCI E-097-2018-0-EA-07 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES EA National Stage 202092044 Pending
NCI E-211-2020-0-US-01 PLK1 POLO BOX DOMAIN INHIBITOR AND METHOD OF TREATING CANCER US 63/082,813 Abandoned
NCI E-176-2014-0-MX-56 Anti-Human Papillomavirus 16 E7 T Cell Receptors MX DIV MX/a/2020/010035 Pending
NCI E-113-2018-0-US-08 COMBINATION OF NEAR INFRARED PHTOIMMUNOTHERAPY TARGETING CANCER CELLS AND HOST-IMMUNE ACTIVATION US National Stage 17/040,426 Abandoned
NIAID E-052-2017-4-EP-50 Trispecific And/or Trivalent Binding Proteins For Prevention Or Treatment Of HIV Infection EP DIV 20197556.2 Abandoned
NHGRI E-217-2007-0-EP-19 N-ACETYL MANNOSAMINE AS A THERAPEUTIC AGENT EP DIV 20197500.0 Pending
NCI E-042-2014-0-EP-25 Chimeric Antigen Receptors Targeting CD-19 EP DIV 20197459.9 Pending
NIMH E-345-2013-0-US-08 Monitoring The Effects Of Sleep Deprivation Using Neuronal Avalanches US CON 17/028,901 Abandoned
NCATS E-133-2020-0-US-01 METHODS AND SYSTEMS FOR EVAPORATION OF SOLVENTS US 63/081,723 Abandoned
NCI E-209-2014-0-US-18 PHOTO-CONTROLLED REMOVAL OF TARGETS IN VITRO AND IN VIVO US CON 17/026,724 11781955 Issued PDF
NIBIB E-054-2018-0-KR-11 CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING PROSTATE CANCER KR National Stage 10-2020-7027109 Issued
NIDA E-017-2018-0-US-04 Novel Biased Potent Opioid-like Agonists As Improved Medications To Treat Chronic And Acute Pain US National Stage 16/982,196 11352365 Issued PDF
NCI E-168-2018-0-PCT-02 METHODS OF ISOLATING T CELL POPULATIONS PCT PCT PCT/US2020/051548 Expired
NCI E-168-2018-0-EP-04 METHODS OF ISOLATING T CELL POPULATIONS EP National Stage 20786149.3 Abandoned
NIAID E-131-2020-4-US-01 Anti-Coronavirus Antibodies And Methods Of Use US 63/080,351 Abandoned
NIDCR E-107-2022-0-US-01 Methods Of Dosing Triphenyl Calcilytic Compounds US 63/080,165 Abandoned
NHGRI E-167-2020-0-US-01 Novel Adeno-associated Viral (AAV) Vectors To Treat Hereditary Methylmalonic Acidemia (MMA) Caused By Methylmalonyl-coA Mutase (MMUT) Deficiency US 63/080,337 Abandoned